Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Hyundai Pharmaceutical discloses new GPR119 receptor agonists

Feb. 20, 2012

Hanmi and AngioLab enter licensing agreement

Feb. 20, 2012

Chinese company divulges new GPR119 receptor agonists and DPP IV inhibitors

Feb. 17, 2012

Takeda reports novel NF-kappa-B activation inhibitors

Feb. 17, 2012

FDA approves new gel for male hypogonadism

Feb. 16, 2012

Glenveigh Medical digoxin antidote gets orphan drug designation

Feb. 16, 2012

Recruitment begins in phase II ISIS-APOCIIIRx trial

Feb. 16, 2012

Trimel provides update on intranasal gel for female anorgasmia

Feb. 16, 2012

Columbia Laboratories transfers progesterone vaginal gel NDA

Feb. 15, 2012

New phase III data support once-weekly exenatide use for diabetes type 2

Feb. 15, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 5, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Axsome’s Auvelity cleared for large Alzheimer’s agitation market
BioWorld
Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
Sonire starts US study of cancer HIFU after $18M series A
BioWorld
Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed...
Coreterra Therapeutics patents agents for schizophrenia
BioWorld Science
Work at Coreterra Therapeutics Inc. has led to the discovery of new thienyl compounds intended for potential use in the treatment of schizophrenia.